Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label extension of Org 50081 in adults with chronic primary insomnia
NL-OMON33547Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esmirtazapine in primary insomnia, sponsored by Merck & Co. Primary endpoint: Safety and tolerability of long-term treatment with Org 50081. Started Feb 2009; status: active, not recruiting.
02
Drugs
esmirtazapine
03
Conditions
primary insomnia
Beyond the preview
Go deeper on NL-OMON33547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33547.